Effects of high flavanol dark chocolate on cardiovascular function and platelet aggregation

Vascular Pharmacology

Volumn 71, Issue , 2015, Pages 70-78

  Rull, Gurvinder ^a   Mohd Zain, Zetty N ^a   Shiel, Julian ^a   Lundberg, Martina H ^a   Collier, David J ^a   Johnston, Atholl ^a   Warner, Timothy D ^a   Corder, Roger ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Blood pressure; Heart rate; PDE inhibitor; Platelet; Pulse pressure amplification ratio

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; FLAVANOL DERIVATIVE; PLACEBO; SALBUTAMOL; THEOBROMINE; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; FLAVONOID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; BORDERLINE HYPERTENSION; CACAO; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART RATE; HIGH FLAVANOL DARK CHOCOLATE; HUMAN; INVESTIGATIVE PROCEDURES; LOW FLAVANOL DARK CHOCOLATE; MALE; PREHYPERTENSION; PRIORITY JOURNAL; PULSE WAVE; RADIAL ARTERY; RADIAL ARTERY APPLANATION TONOMETRY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; TONOMETRY; VASODILATATION; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; BLOOD PRESSURE; CACAO; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FLAVONOIDS; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; TREATMENT OUTCOME; VASODILATION;

EID: 84937974147     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.02.010     Document Type: Article

References (50)

1. Buijsse B., Feskens E.J., Kok F.J., Kromhout D. Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study. Arch Intern Med 2006, 166:411-417.
2. Buijsse B., Weikert C., Drogan D., Bergmann M., Boeing H. Chocolate consumption in relation to blood pressure and risk of cardiovascular disease in German adults. Eur Heart J 2010, 31:1616-1623.
3. Larsson S.C., Virtamo J., Wolk A. Chocolate consumption and risk of stroke: a prospective cohort of men and meta-analysis. Neurology 2012, 79:1223-1229.
4. Janszky I., Mukamal K.J., Ljung R., Ahnve S., Ahlbom A., Hallqvist J. Chocolate consumption and mortality following a first acute myocardial infarction: the Stockholm Heart Epidemiology Program. J Intern Med 2009, 266:248-257.
5. Grassi D., Lippi C., Necozione S., Desideri G., Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr 2005, 81:611-614.
6. Taubert D., Berkels R., Roesen R., Klaus W. Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. JAMA 2003, 290:1029-1030.
7. Grassi D., Necozione S., Lippi C., Croce G., Valeri L., Pasqualetti P., et al. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 2005, 46:398-405.
8. Engler M.B., Engler M.M., Chen C.Y., Malloy M.J., Browne A., Chiu E.Y., et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr 2004, 23:197-204.
9. Heiss C., Jahn S., Taylor M., Real W.M., Angeli F.S., Wong M.L., et al. Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease. J Am Coll Cardiol 2010, 56:218-224.
10. Schroeter H., Heiss C., Balzer J., Kleinbongard P., Keen C.L., Hollenberg N.K., et al. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci U S A 2006, 103:1024-1029.
11. Balzer J., Rassaf T., Heiss C., Kleinbongard P., Lauer T., Merx M., et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. J Am Coll Cardiol 2008, 51:2141-2149.
12. Hermann F., Spieker L.E., Ruschitzka F., Sudano I., Hermann M., Binggeli C., et al. Dark chocolate improves endothelial and platelet function. Heart 2006, 92:119-120.
13. Flammer A.J., Sudano I., Wolfrum M., Thomas R., Enseleit F., Périat D., et al. Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. Eur Heart J 2012, 33:2172-2180.
14. Rein D., Paglieroni T.G., Wun T., Pearson D.A., Schmitz H.H., Gosselin R., et al. Cocoa inhibits platelet activation and function. Am J Clin Nutr 2000, 72:30-35.
15. Holt R.R., Schramm D.D., Keen C.L., Lazarus S.A., Schmitz H.H. Chocolate consumption and platelet function. JAMA 2002, 287:2212-2213.
16. Murphy K.J., Chronopoulos A.K., Singh I., Francis M.A., Moriarty H., Pike M.J., et al. Dietary flavanols and procyanidin oligomers from cocoa (Theobroma cacao) inhibit platelet function. Am J Clin Nutr 2003, 77:1466-1473.
17. Innes A.J., Kennedy G., McLaren M., Bancroft A.J., Belch J.J. Dark chocolate inhibits platelet aggregation in healthy volunteers. Platelets 2003, 14:325-327.
18. Flammer A.J., Hermann F., Sudano I., Spieker L., Hermann M., Cooper K.A., et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007, 116:2376-2382.
19. Gu L., House S.E., Wu X., Ou B., Prior R.L. Procyanidin and catechin contents and antioxidant capacity of cocoa and chocolate products. J Agric Food Chem 2006, 54:4057-4061.
20. Langer S., Marshall L.J., Day A.J., Morgan M.R. Flavanols and methylxanthines in commercially available dark chocolate: a study of the correlation with nonfat cocoa solids. J Agric Food Chem 2011, 59:8435-8441.
21. Butcher R.W., Sutherland E.W. Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem 1962, 237:1244-1250.
22. Fredholm B.B., Bättig K., Holmén J., Nehlig A., Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999, 51:83-133.
23. Yu L., Coelho J.E., Zhang X., Fu Y., Tillman A., Karaoz U., et al. Uncovering multiple molecular targets for caffeine using a drug target validation strategy combining A 2A receptor knockout mice with microarray profiling. Physiol Genomics 2009, 37:199-210.
24. Ried K., Sullivan T.R., Fakler P., Frank O.R., Stocks N.P. Effect of cocoa on blood pressure. Cochrane Database Syst Rev 2012, 8. [CD008893].
25. Kris-Etherton P.M., Dietschy J. Design criteria for studies examining individual fatty acid effects on cardiovascular disease risk factors: human and animal studies. Am J Clin Nutr 1997, 65(5 Suppl):1590S-1596S.
26. 2-adrenoceptor stimulation with flow mediated dilatation. Br J Clin Pharmacol 2007, 65:238-243.
27. Holland D.T., Godfredsen K.A., Page T., Connor J.D. Simple high-performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation. J Chromatogr B Biomed Sci Appl 1998, 707:105-110.
28. Armstrong P.C., Truss N.J., Ali F.Y., Dhanji A.A., Vojnovic I., Zain Z.N., et al. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 2008, 6:1933-1943.
29. Gresele P., Momi S., Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011, 72:634-646.
30. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913. Prospective Studies Collaboration.
31. Akita M., Kuwahara M., Itoh F., Nakano Y., Osakabe N., Kurosawa T., et al. Effects of cacao liquor polyphenols on cardiovascular and autonomic nervous functions in hypercholesterolaemic rabbits. Basic Clin Pharmacol Toxicol 2008, 103:581-587.
32. Curtis B.M., O'Keefe J.H. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc 2002, 77:45-54.
33. Custodis F., Schirmer S.H., Baumhäkel M., Heusch G., Böhm M., Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 2010, 56:1973-1983.
34. Avolio A., Van Bortel L., Boutouyrie P., Cockcroft J.R., McEniery C.M., Protogerou A.D., et al. The role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the Data. Hypertension 2009, 54:375-383.
35. Manisty C.H., Hughes A.D. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 2013, 75:79-92.
36. Williams B. Lacy PS; CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol 2009, 54:705-713.
37. Sharman J.E., McEniery C.M., Dhakam Z.R., Coombes J.S., Wilkinson I.B., Cockcroft J.R. Pulse pressure amplification during exercise is significantly reduced with age and hypercholesterolemia. J Hypertens 2007, 25:1249-1254.
38. Laurent P., Marenco P., Castagna O., Smulyan H., Blacher J., Safar M.E. Differences in central systolic blood pressure and aortic stiffness between aerobically trained and sedentary individuals. J Am Soc Hypertens 2011, 5:85-93.
39. Curtis P.J., Potter J., Kroon P.A., Wilson P., Dhatariya K., Sampson M., et al. Vascular function and atherosclerosis progression after 1 y of flavonoid intake in statin-treated postmenopausal women with type 2 diabetes: a double-blind randomized controlled trial. Am J Clin Nutr 2013, 97:936-942.
40. Pereira T., Maldonado J., Laranjeiro M., Coutinho R., Cardoso E., Andrade I., et al. Central arterial hemodynamic effects of dark chocolate ingestion in young healthy people: a randomized and controlled trial. Cardiol Res Pract 2014, 2014:945951.
41. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
42. Thorin E., Thorin-Trescases N. Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc Res 2009, 84:24-32.
43. Varughese G.I., Lip G.Y. Is hypertension a prothrombotic state?. Curr Hypertens Rep 2005, 7:168-173.
44. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost 2012, 10:167-176.
45. Lopez-Garcia E., Rodriguez-Artalejo F., Rexrode K.M., Logroscino G., Hu F.B., van Dam R.M. Coffee consumption and risk of stroke in women. Circulation 2009, 119:1116-1123.
46. Larsson S.C., Virtamo J., Wolk A. Coffee consumption and risk of stroke in women. Stroke 2011, 42:908-912.
47. Kokubo Y., Iso H., Saito I., Yamagishi K., Yatsuya H., Ishihara J., et al. The impact of green tea and coffee consumption on the reduced risk of stroke incidence in Japanese population: the Japan public health center-based study cohort. Stroke 2013, 44:1369-1374.
48. Kris-Etherton P.M., Derr J., Mitchell D.C., Mustad V.A., Russell M.E., McDonnell E.T., et al. The role of fatty acid saturation on plasma lipids, lipoproteins, and apolipoproteins: I. Effects of whole food diets high in cocoa butter, olive oil, soybean oil, dairy butter, and milk chocolate on the plasma lipids of young men. Metabolism 1993, 42:121-129.
49. Sever P.S., Poulter N.R., Elliott W.J., Jonsson M.C., Black H.R. Blood pressure reduction is not the only determinant of outcome. Circulation 2006, 113:2754-2774.
50. Duprez D.A. Systolic hypertension in the elderly: addressing an unmet need. Am J Med 2008, 121:179-184. (e3).